awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q37022524-A9553353-EBCF-49A5-AD68-98E387052DA0
Q37022524-A9553353-EBCF-49A5-AD68-98E387052DA0
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37022524-A9553353-EBCF-49A5-AD68-98E387052DA0
The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer
P2860
Q37022524-A9553353-EBCF-49A5-AD68-98E387052DA0
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37022524-A9553353-EBCF-49A5-AD68-98E387052DA0
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
f92d4f27d21d2f96a2181e2f2ef94349db3999bb
P2860
Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia.